SPECIALTY GUIDELINE MANAGEMENT

PROFILNINE (factor IX complex [human])

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

A. FDA-Approved Indication

Hemophilia B

B. Compendial Uses

- 1. Bleeding due to low levels of liver-dependent coagulation factors
- 2. Factor II deficiency

All other indications are considered experimental/investigational and not medically necessary.

II. CRITERIA FOR INITIAL APPROVAL

A. Hemophilia B

Authorization of 12 months may be granted for treatment of hemophilia B.

B. Bleeding Due to Low Levels of Liver-dependent Coagulation Factors

Authorization of 12 months may be granted for treatment of bleeding due to low levels of liver-dependent coagulation factors.

C. Factor II Deficiency

Authorization of 12 months may be granted for treatment of factor II deficiency.

III. CONTINUATION OF THERAPY

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization for an indication listed in Section II when the member is experiencing benefit from therapy (e.g., reduced frequency or severity of bleeds).

IV. REFERENCES

- 1. Profilnine [package insert]. Los Angeles, CA: Grifols Biologicals, LLC; June 2018.
- 2. Micromedex Solutions [database online]. Ann Arbor, MI: Truven Health Analytics Inc. Updated periodically www.micromedexsolutions.com [available with subscription]. Accessed November 25, 2020.

Factor IX Complex 1949-A SGM P2021.docx

© 2020 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.



Reference	number(s)
1949-A	

3. National Hemophilia Foundation. MASAC recommendations concerning products licensed for the treatment of hemophilia and other bleeding disorders. Revised August 2020. MASAC Document #263. https://www.hemophilia.org/sites/default/files/document/files/263_treatment.pdf. Accessed November 20, 2020.

Factor IX Complex 1949-A SGM P2021.docx

© 2020 CVS Caremark. All rights reserved.

permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.



This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written